{"id":79834,"date":"2026-04-22T00:05:21","date_gmt":"2026-04-22T00:05:21","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/"},"modified":"2026-04-22T00:05:21","modified_gmt":"2026-04-22T00:05:21","slug":"vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/","title":{"rendered":"ViGenCell&#8217;s VT-EBV-N Selected for Oral Presentation at ASCO 2026"},"content":{"rendered":"<div>\n<table name=\"logo_release\" border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2961307\/ViGenCell_Logo.jpg?p=medium600\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\"><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p class=\"prntac\">Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting<\/p>\n<p><span class=\"legendSpanClass\">SEOUL, South Korea<\/span>, April 22, 2026 \/PRNewswire\/ &#8212;\u00a0ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that results from its Phase 2 clinical study of VT-EBV-N have been selected for an oral presentation at the ASCO Annual Meeting 2026.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<p>The ASCO Annual Meeting, to be held from May 29 to June 2, 2026 in Chicago, Illinois, is one of the world&#8217;s largest and most influential oncology conferences, where cutting-edge clinical data are presented and discussed among oncology experts. Among the thousands of abstracts submitted each year, only a limited number are selected for oral presentation, representing a highly selective subset of accepted submissions.<\/p>\n<p>The presentation will be delivered by Dr. Young-Woo Jeon of Yeouido St. Mary&#8217;s Hospital, who served as the principal investigator of the study.<\/p>\n<p>VT-EBV-N is an Epstein-Barr virus (EBV)-specific T cell therapy being developed for the treatment of NK\/T-cell lymphoma, a rare and aggressive malignancy with a high risk of relapse.<\/p>\n<p>According to the company, the Phase 2 study demonstrated clinically meaningful outcomes, supporting the potential of VT-EBV-N as a differentiated therapeutic option in this setting. Detailed results will be presented during the official session at ASCO 2026.<\/p>\n<p>&#8220;Being selected for an oral presentation at ASCO highlights the clinical strength and growing momentum of our program,&#8221; said Pyung-Suk Ki, Chief Executive Officer of ViGenCell. &#8220;We look forward to sharing the full data with the global oncology community and further accelerating our global development and partnering efforts.&#8221;<\/p>\n<p><b>About VT-EBV-N<\/b><\/p>\n<p>VT-EBV-N is an autologous EBV-specific T cell therapy designed to selectively target EBV-infected tumor cells. The therapy is being investigated for its potential to reduce relapse risk and improve clinical outcomes in patients with NK\/T-cell lymphoma. Detailed clinical data from the Phase 2 study will be presented at the ASCO Annual Meeting 2026.<\/p>\n<p><b>About ViGenCell Inc.<\/b><\/p>\n<p>ViGenCell Inc. is a clinical-stage biotechnology company based in South Korea, focused on the development of immune cell therapies, including both allogeneic (NK cell-based) and autologous (T cell-based) approaches.<\/p>\n<p>The company operates its own GMP manufacturing facility and collaborates with a network of clinical institutions to advance its pipeline through clinical development, with a focus on delivering real-world therapeutic impact.<\/p>\n<p>Its lead program, VT-EBV-N, has completed a Phase 2 study in NK\/T-cell lymphoma. In addition, ViGenCell is developing next-generation cell therapy programs based on its EiNK&#x2122; platform in collaboration with Therabest, including &#8216;VC302&#8217; for glioblastoma and &#8216;VC420&#8217; for hepatocellular carcinoma, both currently in preclinical development.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 22, 2026 \/PRNewswire\/ &#8212;\u00a0ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on advanced cell therapies, today announced that results from its Phase 2 clinical study of VT-EBV-N have been selected [&#8230;]\n","protected":false},"author":1,"featured_media":79226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-79834","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ViGenCell&#039;s VT-EBV-N Selected for Oral Presentation at ASCO 2026 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ViGenCell&#039;s VT-EBV-N Selected for Oral Presentation at ASCO 2026\" \/>\n<meta property=\"og:description\" content=\"Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 22, 2026 \/PRNewswire\/ &#8212;\u00a0Vi\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-22T00:05:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1075\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"ViGenCell&#8217;s VT-EBV-N Selected for Oral Presentation at ASCO 2026\",\"datePublished\":\"2026-04-22T00:05:21+00:00\",\"dateModified\":\"2026-04-22T00:05:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/\"},\"wordCount\":431,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/\",\"name\":\"ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-04-22T00:05:21+00:00\",\"dateModified\":\"2026-04-22T00:05:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ViGenCell&#8217;s VT-EBV-N Selected for Oral Presentation at ASCO 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/","og_locale":"en_US","og_type":"article","og_title":"ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026","og_description":"Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 22, 2026 \/PRNewswire\/ &#8212;\u00a0Vi","og_url":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-04-22T00:05:21+00:00","og_image":[{"width":1075,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"ViGenCell&#8217;s VT-EBV-N Selected for Oral Presentation at ASCO 2026","datePublished":"2026-04-22T00:05:21+00:00","dateModified":"2026-04-22T00:05:21+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/"},"wordCount":431,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/","url":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/","name":"ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-04-22T00:05:21+00:00","dateModified":"2026-04-22T00:05:21+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/vigencells-vt-ebv-n-selected-for-oral-presentation-at-asco-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"ViGenCell&#8217;s VT-EBV-N Selected for Oral Presentation at ASCO 2026"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/79834","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=79834"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/79834\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/79226"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=79834"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=79834"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=79834"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}